138 related articles for article (PubMed ID: 8750531)
1. Differential distribution of ErbB-2 and pS2 proteins in ductal carcinoma in situ of the breast.
Inaji H; Koyama H; Motomura K; Noguchi S
Breast Cancer Res Treat; 1996; 37(1):89-92. PubMed ID: 8750531
[TBL] [Abstract][Full Text] [Related]
2. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.
Poller DN; Silverstein MJ; Galea M; Locker AP; Elston CW; Blamey RW; Ellis IO
Mod Pathol; 1994 Feb; 7(2):257-62. PubMed ID: 7911998
[TBL] [Abstract][Full Text] [Related]
3. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67.
Mack L; Kerkvliet N; Doig G; O'Malley FP
Hum Pathol; 1997 Aug; 28(8):974-9. PubMed ID: 9269835
[TBL] [Abstract][Full Text] [Related]
4. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein.
Leal CB; Schmitt FC; Bento MJ; Maia NC; Lopes CS
Cancer; 1995 Apr; 75(8):2123-31. PubMed ID: 7697603
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast.
Luqmani YA; Campbell T; Soomro S; Shousha S; Rio MC; Coombes RC
Br J Cancer; 1993 Apr; 67(4):749-53. PubMed ID: 8385977
[TBL] [Abstract][Full Text] [Related]
6. Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins.
Quinn CM; Ostrowski JL; Harkins L; Rice AJ; Loney DP
Histopathology; 1998 Dec; 33(6):531-6. PubMed ID: 9870147
[TBL] [Abstract][Full Text] [Related]
7. Distribution of Hsp-27 and HER-2/neu in in situ and invasive ductal breast carcinomas.
Storm FK; Gilchrist KW; Warner TF; Mahvi DM
Ann Surg Oncol; 1995 Jan; 2(1):43-8. PubMed ID: 7530588
[TBL] [Abstract][Full Text] [Related]
8. p53, ErbB2, and TAG-72 expression in the spectrum of ductal carcinoma in situ of the breast classified by the Van Nuys system.
Kanthan R; Xiang J; Magliocco AM
Arch Pathol Lab Med; 2000 Feb; 124(2):234-9. PubMed ID: 10656732
[TBL] [Abstract][Full Text] [Related]
9. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast.
Rudas M; Neumayer R; Gnant MF; Mittelböck M; Jakesz R; Reiner A
Eur J Cancer; 1997 Jan; 33(1):39-44. PubMed ID: 9071897
[TBL] [Abstract][Full Text] [Related]
10. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.
Baqai T; Shousha S
Histopathology; 2003 May; 42(5):440-7. PubMed ID: 12713620
[TBL] [Abstract][Full Text] [Related]
11. Correlations between the mammographic features of ductal carcinoma in situ (DCIS) and C-erbB-2 oncogene expression. Nottingham Breast Team.
Evans AJ; Pinder SE; Ellis IO; Sibbering DM; Elston CW; Poller DN; Wilson AR
Clin Radiol; 1994 Aug; 49(8):559-62. PubMed ID: 7955870
[TBL] [Abstract][Full Text] [Related]
12. Intestinal trefoil factor (TFF 3) and pS2 (TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are co-expressed in normal, hyperplastic, and neoplastic human breast epithelium.
Poulsom R; Hanby AM; Lalani EN; Hauser F; Hoffmann W; Stamp GW
J Pathol; 1997 Sep; 183(1):30-8. PubMed ID: 9370944
[TBL] [Abstract][Full Text] [Related]
13. The evaluation of the immunoexpression of Her2÷neu oncoprotein in ductal carcinoma in situ in association with invasive ductal carcinoma of the breast.
Fota GL; Stepan A; Ciurea RN
Rom J Morphol Embryol; 2012; 53(3 Suppl):805-10. PubMed ID: 23188444
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion.
Asch HL; Winston JS; Edge SB; Stomper PC; Asch BB
Breast Cancer Res Treat; 1999 May; 55(2):179-88. PubMed ID: 10481945
[TBL] [Abstract][Full Text] [Related]
15. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
16. Multiple developmental pathways of highly aggressive breast cancers disclosed by comparison of histological grades and c-erbB-2 expression patterns in both the non-invasive and invasive portions.
Tsuda H; Hirohashi S
Pathol Int; 1998 Jul; 48(7):518-25. PubMed ID: 9701014
[TBL] [Abstract][Full Text] [Related]
17. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems.
Leong AS; Sormunen RT; Vinyuvat S; Hamdani RW; Suthipintawong C
Am J Clin Pathol; 2001 May; 115(5):709-18. PubMed ID: 11345835
[TBL] [Abstract][Full Text] [Related]
18. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
[TBL] [Abstract][Full Text] [Related]
19. c-erbB-3 protein expression in ductal carcinoma in situ of the breast.
Bobrow LG; Millis RR; Happerfield LC; Gullick WJ
Eur J Cancer; 1997 Oct; 33(11):1846-50. PubMed ID: 9470844
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast.
Lodato RF; Maguire HC; Greene MI; Weiner DB; LiVolsi VA
Mod Pathol; 1990 Jul; 3(4):449-54. PubMed ID: 2170971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
